About this trial
Coronary artery bypass graft (CABG) surgery is still the standard treatment of coronary revascularization for patients with severe coronary artery disease (CAD). Graft patency, together with completeness of revascularization, is a major determinant of long-term outcome following CABG. The surgical procedure elicits a persistent systemic inflammatory response associated with the activation of the hemostatic system leading to perturbation of endothelial and vascular function and activation of platelets and leukocytes. All of these events are the main players responsible for the early and late graft failure in a significant percentage of patients.
Eligibility criteria
Qualifiers
between the ages of 40 and 80
Ejection fraction> 30%
coronary artery bypass surgery
informed consent
Disqualifiers
emergency intervention
changes in liver or kidney function
changes in coagulation factors
associated interventions (valve replacement, carotid endarterectomy)
Trial design
Treatments tested in this trial
- Not listed